amyloidogenic

LC kinetic stabilizer-1 is a potent, selective kinetic stabilizer for amyloidogenic immunoglobulin light chains, demonstrating EC50 values of 140 nM for WIL-FL* and 74.1 nM for WIL-FL*T46L/F49Y, respectively. Notably, WIL-FL represents an amyloidogenic FL LC dimer.

Eprodisate is a novel compound specifically developed to disrupt the interactions between amyloidogenic proteins and glycosaminoglycans, effectively impeding the polymerization of amyloid fibrils and their deposition in tissues. This compound shows potential for delaying the advancement of AA amyloidosis-related renal disease and could apply to various forms of amyloidosis.

NQTrp is an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects.

PD 142505-0028, a functionally M1-selective muscarinic agonist, rapidly increases glutamate but not aspartate concentrations in the striatum of anesthetized rats. Additionally, it inhibited production of amyloidogenic A beta and increased secretion of sol

Tafamidis-d3 is a deuterated compound of Tafamidis. Tafamidis has a CAS number of 594839-88-0. Tafamidis is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs. It binds to TTR with negative cooperativity (Kd1: 3 nM; Kd2: 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation. Tafamidis stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s: 2.7-3.2 μM) under fibril-promoting, denaturing, and physiological conditions in vitro. It stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 μM. Formulations containing tafamidis have been used for the treatment of familial amyloid polyneuropathy.

Tafamidis (Fx-1006A) is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs. It binds to TTR with negative cooperativity (Kd1: 3 nM; Kd2: 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation. Tafamidis stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s: 2.7-3.2 μM) under fibril-promoting, denaturing, and physiological conditions in vitro. It stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 μM. Formulations containing tafamidis have been used for the treatment of familial amyloid polyneuropathy.

Acetyl-PHF5 amide is a tau peptide with amyloidogenic properties. It can undergo polymerization to form filamentous structures [1].

Pramlintide is a non-amyloidogenic analog of the antidiabetic peptide hormone amylin that contains proline residues substituted at positions 25, 28, and 29. It stimulates cAMP production in HEK293 cells expressing human amylin receptor 1a (AMY1a), AMY2a, and AMY3a (EC50s = 0.35, 22.9, and 0.89 nM, respectively). Pramlintide inhibits human islet amyloid polypeptide fibrilization in a concentration-dependent manner. In vivo, pramlintide (200 pg/kg) reduces brain levels of amyloid-β (1-40) and increases spontaneous alternation in the Y-maze in the Tg2576 transgenic mouse model of Alzheimer's disease.

MRZ-99030 is an Aβ aggregation modulator. MRZ-99030 triggers a non-amyloidogenic aggregation pathway, thereby reducing the amount of intermediate toxic soluble oligomeric Aβ species.

SNNF(N-Me)GA(N-Me)ILSS is a biologically active peptide containing double N-methylated derivatives of an amyloidogenic and cytotoxic partial IAPP sequence.

SNNF(N-Me)GA(N-Me)IL is a biologically active peptide featuring double N-methylated derivatives of a partial IAPP sequence, known for its amyloidogenic and cytotoxic properties.

LC Kinetic Stabilizer-2 is a powerful stabilizer for amyloidogenic immunoglobulin light chains (LC), demonstrating significant efficacy with an EC50 of 24 nM.

β-Amyloid (1-16) is an amyloidogenic protein fragment derived from the β-amyloid sequence, known for its ability to bind metal ions, indicating its role in metal-binding processes. β-Amyloid, a peptide, is responsible for forming amyloid plaques in the brains of people with Alzheimer's disease (AD).

NF(N-Me)GA(N-Me)IL is a biologically active peptide, representing a modified segment (amino acids 22 to 27) of the human islet amyloid polypeptide (hIAPP) sequence NFGAIL. This modification includes N-methylations at G24 and I26, transforming the amyloidogenic and cytotoxic nature of the original sequence into a non-amyloidogenic and non-cytotoxic variant. Moreover, the peptide maintains the ability to bind with high affinity to full-length hIAPP, effectively inhibiting its fibril formation.